NASDAQ: ETONEton Pharmaceuticals Inc Stock
$3.28+0.03 (+0.92%)
Updated Apr 23, 2024
ETON Price
$3.28
Fair Value Price
N/A
Market Cap
$84.26M
52 Week Low
$2.42
52 Week High
$5.81
P/E
-82x
P/B
5.44x
P/S
3.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.64M
Earnings
-$936.00k
Gross Margin
67.6%
Operating Margin
-3.65%
Profit Margin
-2.9%
Debt to Equity
1.05
Operating Cash Flow
$7M
Beta
0.83
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ETON Overview
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ETON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ETON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ETON is poor value based on its book value relative to its share price (5.44x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.07x)
P/B vs Industry Valuation
ETON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ETON due diligence checks available for Premium users.
Be the first to know about important ETON news, forecast changes, insider trades & much more!
ETON News
Valuation
ETON fair value
Fair Value of ETON stock based on Discounted Cash Flow (DCF)
Price
$3.28
Fair Value
$5.03
Undervalued by
34.74%
ETON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ETON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-82x
Industry
46.85x
Market
41.92x
ETON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.44x
Industry
2.07x
ETON is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ETON's financial health
Profit margin
Revenue
$8.3M
Net Income
-$2.3M
Profit Margin
-27.1%
ETON's Earnings (EBIT) of -$1.19M... subscribe to Premium to read more.
Interest Coverage Financials
ETON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.7M
Liabilities
$16.3M
Debt to equity
1.05
ETON's short-term assets ($26.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ETON's short-term assets ($26.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ETON's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ETON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$387.0k
Investing
-$775.0k
Financing
-$294.0k
ETON's operating cash flow ($6.82M)... subscribe to Premium to read more.
Debt Coverage Financials
ETON vs Pharmaceutical Stocks
Eton Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.